|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-8-28
|
|
pubmed:abstractText |
Pharmacologic studies have implicated dopamine D1-like receptors in the development of dopamine precursor molecule 3,4-dihydroxyphenyl-L-alanine (L-DOPA)-induced dyskinesias and associated molecular changes in hemiparkinsonian mice. However, pharmacologic agents for D1 or D2 receptors also recognize other receptor family members. Genetic inactivation of the dopamine D1 or D2 receptor was used to define the involvement of these receptor subtypes.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiparkinson Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Dynorphins,
http://linkedlifedata.com/resource/pubmed/chemical/Extracellular Signal-Regulated MAP...,
http://linkedlifedata.com/resource/pubmed/chemical/Histones,
http://linkedlifedata.com/resource/pubmed/chemical/Levodopa,
http://linkedlifedata.com/resource/pubmed/chemical/Oxidopamine,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-fos,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Dopamine D1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Dopamine D2,
http://linkedlifedata.com/resource/pubmed/chemical/Tyrosine 3-Monooxygenase
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1873-2402
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
603-13
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19520364-Acetylation,
pubmed-meshheading:19520364-Analysis of Variance,
pubmed-meshheading:19520364-Animals,
pubmed-meshheading:19520364-Antiparkinson Agents,
pubmed-meshheading:19520364-Behavior, Animal,
pubmed-meshheading:19520364-Corpus Striatum,
pubmed-meshheading:19520364-Disease Models, Animal,
pubmed-meshheading:19520364-Dynorphins,
pubmed-meshheading:19520364-Dyskinesia, Drug-Induced,
pubmed-meshheading:19520364-Extracellular Signal-Regulated MAP Kinases,
pubmed-meshheading:19520364-Functional Laterality,
pubmed-meshheading:19520364-Gene Expression Regulation,
pubmed-meshheading:19520364-Histones,
pubmed-meshheading:19520364-Levodopa,
pubmed-meshheading:19520364-Mice,
pubmed-meshheading:19520364-Mice, Knockout,
pubmed-meshheading:19520364-Motor Activity,
pubmed-meshheading:19520364-Neurons,
pubmed-meshheading:19520364-Oxidopamine,
pubmed-meshheading:19520364-Parkinsonian Disorders,
pubmed-meshheading:19520364-Phosphorylation,
pubmed-meshheading:19520364-Proto-Oncogene Proteins c-fos,
pubmed-meshheading:19520364-Receptors, Dopamine D1,
pubmed-meshheading:19520364-Receptors, Dopamine D2,
pubmed-meshheading:19520364-Statistics as Topic,
pubmed-meshheading:19520364-Tyrosine 3-Monooxygenase
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
|
|
pubmed:affiliation |
Cajal Institute, Consejo Superior de Investigaciones Científicas and Centro de Investigación Biomédica en Red para Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
